356 related articles for article (PubMed ID: 21212709)
1. Prevention of corneal neovascularization: comparison of different doses of subconjunctival bevacizumab with its topical form in experimental rats.
Hashemian MN; Z-Mehrjardi H; Moghimi S; Tahvildari M; Mojazi-Amiri H
Ophthalmic Res; 2011; 46(1):50-4. PubMed ID: 21212709
[TBL] [Abstract][Full Text] [Related]
2. Prevention and treatment of corneal neovascularization: comparison of different doses of subconjunctival bevacizumab with corticosteroid in experimental rats.
Hashemian MN; Moghimi S; Kiumehr S; Riazi M; Amoli FA
Ophthalmic Res; 2009; 42(2):90-5. PubMed ID: 19546599
[TBL] [Abstract][Full Text] [Related]
3. Topical and subconjunctival bevacizumab for corneal neovascularization in an experimental rat model.
Öner V; Küçükerdönmez C; Akova YA; Çolak A; Karalezli A
Ophthalmic Res; 2012; 48(3):118-23. PubMed ID: 22538642
[TBL] [Abstract][Full Text] [Related]
4. Effect of subconjunctival bevacizumab (Avastin) on experimental corneal neovascularization in guinea pigs.
Hurmeric V; Mumcuoglu T; Erdurman C; Kurt B; Dagli O; Durukan AH
Cornea; 2008 Apr; 27(3):357-62. PubMed ID: 18362668
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of corneal neovascularization by subconjunctival bevacizumab in an animal model.
Papathanassiou M; Theodossiadis PG; Liarakos VS; Rouvas A; Giamarellos-Bourboulis EJ; Vergados IA
Am J Ophthalmol; 2008 Mar; 145(3):424-431. PubMed ID: 18207123
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of experimental corneal neovascularization by using subconjunctival injection of bevacizumab (Avastin).
Kim TI; Kim SW; Kim S; Kim T; Kim EK
Cornea; 2008 Apr; 27(3):349-52. PubMed ID: 18362666
[TBL] [Abstract][Full Text] [Related]
7. Subconjunctival injection of bevacizumab (avastin) on corneal neovascularization in different rabbit models of corneal angiogenesis.
Chen WL; Lin CT; Lin NT; Tu IH; Li JW; Chow LP; Liu KR; Hu FR
Invest Ophthalmol Vis Sci; 2009 Apr; 50(4):1659-65. PubMed ID: 18997093
[TBL] [Abstract][Full Text] [Related]
8. The inhibitory effect of different concentrations of topical bevacizumab on corneal neovascularization.
Habot-Wilner Z; Barequet IS; Ivanir Y; Moisseiev J; Rosner M
Acta Ophthalmol; 2010 Dec; 88(8):862-7. PubMed ID: 19549103
[TBL] [Abstract][Full Text] [Related]
9. Effect of subconjunctival and intraocular bevacizumab injections on corneal neovascularization in a mouse model.
Avisar I; Weinberger D; Kremer I
Curr Eye Res; 2010 Feb; 35(2):108-15. PubMed ID: 20136420
[TBL] [Abstract][Full Text] [Related]
10. The effect of subconjunctival suramin on corneal neovascularization in rabbits.
Lee HS; Chung SK
Cornea; 2010 Jan; 29(1):86-92. PubMed ID: 19907290
[TBL] [Abstract][Full Text] [Related]
11. Subconjunctival bevacizumab for corneal neovascularization.
Zaki AA; Farid SF
Acta Ophthalmol; 2010 Dec; 88(8):868-71. PubMed ID: 19519730
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of corneal neovascularization by subconjunctival and topical bevacizumab and sunitinib in a rabbit model.
Ko BY; Kim YS; Baek SG; Lee GW; Kim JM; Jean WS; Lee NS; Kang J
Cornea; 2013 May; 32(5):689-95. PubMed ID: 23377751
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the effects of subconjunctival and topical anti-VEGF therapy (bevacizumab) on experimental corneal neovascularization.
Ozdemir O; Altintas O; Altintas L; Ozkan B; Akdag C; Yüksel N
Arq Bras Oftalmol; 2014 Aug; 77(4):209-13. PubMed ID: 25410169
[TBL] [Abstract][Full Text] [Related]
14. Combined use of subconjunctival and intracorneal bevacizumab injection for corneal neovascularization.
Yeung SN; Lichtinger A; Kim P; Amiran MD; Slomovic AR
Cornea; 2011 Oct; 30(10):1110-4. PubMed ID: 21673570
[TBL] [Abstract][Full Text] [Related]
15. Comparative study of tacrolimus and bevacizumab on corneal neovascularization in rabbits.
Park JH; Joo CK; Chung SK
Cornea; 2015 Apr; 34(4):449-55. PubMed ID: 25651492
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of corneal neovascularization by topical bevacizumab (Anti-VEGF) and Sunitinib (Anti-VEGF and Anti-PDGF) in an animal model.
Pérez-Santonja JJ; Campos-Mollo E; Lledó-Riquelme M; Javaloy J; Alió JL
Am J Ophthalmol; 2010 Oct; 150(4):519-528.e1. PubMed ID: 20591397
[TBL] [Abstract][Full Text] [Related]
17. Bevacizumab inhibits corneal neovascularization in an alkali burn induced model of corneal angiogenesis.
Hosseini H; Nejabat M; Mehryar M; Yazdchi T; Sedaghat A; Noori F
Clin Exp Ophthalmol; 2007 Nov; 35(8):745-8. PubMed ID: 17997779
[TBL] [Abstract][Full Text] [Related]
18. The anti-inflammatory effect of subconjunctival bevacizumab on chemically burned rat corneas.
Oh JY; Kim MK; Shin MS; Lee HJ; Lee JH; Wee WR
Curr Eye Res; 2009 Feb; 34(2):85-91. PubMed ID: 19219678
[TBL] [Abstract][Full Text] [Related]
19. The effect of subconjuctival combined treatment of bevacizumab and triamcinolone acetonide on corneal neovascularization in rabbits.
Kang S; Chung SK
Cornea; 2010 Feb; 29(2):192-6. PubMed ID: 20098156
[TBL] [Abstract][Full Text] [Related]
20. Subconjunctival injection of low-molecular-weight heparin-taurocholate 7 inhibits corneal neovascularization.
Yoon SY; Kim JY; Kim ES; Kim SY; Kim MJ; Tchah H
Cornea; 2013 Nov; 32(11):1488-92. PubMed ID: 24055905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
